Publications by authors named "I Elomaa"
Background: Premenopausal patients treated with adjuvant chemotherapy often develop early menopause and thus, may encounter significant bone loss. We studied the long-term effects of chemotherapy-induced ovarian dysfunction on bone mineral density in breast cancer patients.
Material And Methods: The effect of menstrual status after adjuvant chemotherapy on bone mineral density (BMD) was examined in 29 premenopausal breast cancer patients.
Article Synopsis
- The study investigates blood flow and glucose metabolism in untreated musculoskeletal tumors using PET imaging techniques.
- Six patients with various types of sarcomas underwent PET scans and were assessed for blood flow and glucose uptake, with some receiving chemotherapy during the trial.
- Results showed a range of blood flow rates and glucose uptake between bone tumors and soft-tissue sarcomas, highlighting a potential relationship between high blood flow in osteosarcoma and longer survival, while the link between glucose metabolism and outcomes requires more exploration.
Purpose: We have previously reported that 3-year adjuvant clodronate treatment prevents bone loss in breast cancer patients. Here we report the 10-year follow-up data of clodronate in the prevention of treatment-related osteoporosis in women with early-stage breast cancer.
Patients And Methods: Two hundred sixty-eight pre- and postmenopausal, node-positive breast cancer patients were randomly assigned to clodronate, 1.
5-Fluorouracil (5-FU)-based chemotherapy is frequently associated with diarrhoea. We compared two 5-FU-based regimens and the effect of Lactobacillus and fibre supplementation on treatment tolerability. Patients diagnosed with colorectal cancer (n=150) were randomly allocated to receive monthly 5-FU and leucovorin bolus injections (the Mayo regimen) or a bimonthly 5-FU bolus plus continuous infusion (the simplified de Gramont regimen) for 24 weeks as postoperative adjuvant therapy.
View Article and Find Full Text PDFArticle Synopsis
- Malignant fibrous histiocytoma (MFH) of bone is a rare and aggressive tumor, with a study of 26 cases revealing significant genetic alterations through comparative genomic hybridization (CGH) analysis.
- Out of the tumors analyzed, 89% showed DNA sequence copy number changes, with gains occurring more frequently than losses, highlighting specific regions of interest associated with the mutations.
- The study's findings underscore the unique genetic profile of bone MFH compared to other tumors, reinforcing its classification as a distinct and highly malignant bone tumor.